Suppression of murine cardiac allograft arteriopathy by long-term blockade of CD40-CD154 interactions

Circulation

Volumn 105, Issue 13, 2002, Pages 1609-1614

  Wang, Catherine Y ^a   Mazer, Sean P ^a   Minamoto, Kanji ^a   Takuma, Shin ^a   Homma, Shunichi ^a   Yellin, Michael ^a   Chess, Leonard ^a   Fard, Ali ^a   Kalled, Susan L ^b   Oz, Mehmet C ^a   Pinsky, David J ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b BIOGEN   (United States)

Author keywords

Cell adhesion molecules; Immunology; Rejection; Transplantation

Indexed keywords

ANTIBODY; CD40 ANTIGEN; CD40 LIGAND; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTERY DISEASE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; GRAFT REJECTION; HEART TRANSPLANTATION; INTIMA; MACROPHAGE; MALE; MOUSE; NONHUMAN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; CD40 LIGAND; CELL ADHESION MOLECULES; CELL MOVEMENT; CORONARY ARTERIOSCLEROSIS; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; KINETICS; MALE; MICE; T-LYMPHOCYTES;

EID: 0037007040     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000013022.11250.30     Document Type: Article

References (21)

1. Early development of accelerated graft coronary artery disease: Risk factors and course
2. Cardiac graft vascular disease: Nonselective involvement of large and small vessels
3. Human coronary transplantation-associated arteriosclerosis: Evidence for a chronic immune reaction to activated graft endothelial cells
4. CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets
5. Long-term acceptance of skin and cardiac allografis after CD40 and CD28 pathways
6. Costimulatory function and expression of CD40 ligand, CD80 and CD86 in vascularized murine cardiac allograft rejection
7. cAMP pulse during preservation inhibits the late development of cardiac isograft and allograft vasculopathy
8. Restoration of the cAMP second messenger pathway enhances cardiac preservation for transplantation in a heterotopic rat model
9. Noninvasive assessment and necropsy validation of changes in left ventricular mass and function in ascending aortic banded mice
10. Cardiac graft intercellular adhesion molecule-1 (ICAM-I) and Interleukin-1 expression mediate primary isograft failure and induction of ICAM- 1 in organs remote from the site of transplantation
11. Coronary atherosclerosis in transplanted mouse hearts: Effects of treatment with monoclonal antibodies to intercellular adhesion molecule-1 and leukocyte function-associated antigen-1
12. CD40 and CD40 ligand (CD154) are co-expressed on microvessels in vivo in human cardiac allograft rejection
13. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
14. Treatment with humanized monoclonal antibody against CD154 prevents acute renal altografi rejection in nonhuman primates
15. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice
16. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signalling in atherosclerosis
17. Reduction of atherosclerosis in mice by inhibition of CD40 signalling
18. Analysis of CD154 and CD40 expression in native coronary atherosclerosis and transplant associated coronary artery disease
19. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis
20. Inhibition of accelerated coronary atherosclerosis with short-term blockade of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 in a heterotopic murine model of heart transplantation
21. Requirements for the promotion of allogeneic engraftment by anti-CDI54 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions